# A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.

> **NCT03681548** · PHASE1 · COMPLETED · sponsor: **Ayana Pharma Ltd.,** · enrollment: 52 (actual)

## Conditions studied

- Ovarian Cancer Recurrent

## Interventions

- **DRUG:** Doxorubicin Hydrochloride Liposome Injection

## Key facts

- **NCT ID:** NCT03681548
- **Lead sponsor:** Ayana Pharma Ltd.,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-29
- **Primary completion:** 2019-02-08
- **Final completion:** 2019-03-07
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2019-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03681548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03681548, "A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03681548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*